Education
About Us
Working with TipRanks
Follow Us
Alumis Inc. (ALMS)
NASDAQ:ALMS
ALMS Stock Chart & Stats
$26.12
-$0.47(-5.84%)
At close: 4:00 PM EST
$26.12
-$0.47(-5.84%)
Day’s Range― - ―
52-Week Range$2.76 - $28.29
Previous CloseN/A
Volume29.29K
Average Volume (3M)4.57M
Market Cap
$3.27B
Enterprise Value$2.69B
Total Cash (Recent Filing)$377.72M
Total Debt (Recent Filing)$37.80M
Price to Earnings (P/E)―
Beta-1.78
Next Earnings
Mar 25, 2026EPS Estimate
-0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.06
Shares Outstanding117,506,000
10 Day Avg. Volume1,547,540
30 Day Avg. Volume4,567,732
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.86
Price to Sales (P/S)0.00
P/FCF Ratio-0.87
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue121.70
Enterprise Value/Gross Profit126.39
Enterprise Value/Ebitda-6.34
Forecast
1Y Price Target
$37.57Price Target Upside43.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-3.05
Revenue Forecast (FY)$6.99M
Bulls Say, Bears Say
Bulls Say
Comparative Clinical EfficacyPhase 3 data indicate envudeucitinib achieved superior skin clearance versus the approved oral therapy and other oral TYK2 benchmarks, suggesting potential to shift prescriptions within the oral treatment segment.
Financial Runway And Pipeline DepthReduction in R&D and SG&A expenses is expected to extend the company's cash runway into 2027 while an active, catalyst-rich pipeline beyond envu offers multiple potential growth opportunities.
Safety And TolerabilitySafety findings were consistent with earlier studies, showing no new safety signals and mostly mild-to-moderate adverse events, which supports broader clinical adoption and physician confidence.
Bears Say
Competitive Threat From Long-acting InjectablesLong-acting injectable therapies that many patients and physicians view as offering near‑curative convenience could limit market uptake for a continuous daily oral therapy like envudeucitinib.
Data Transparency And Durability ConcernsLimited disclosure of full Phase 3 results creates uncertainty about whether deep responses persist beyond reported assessment windows and raises questions about trial-to-trial consistency and handling of missing data.
Development And Regulatory RiskRisks include potential delays in advancing envu into pivotal trials and the possibility of failing to secure approval in major markets, which would affect commercial prospects.
Alumis Inc. News
ALMS FAQ
What was Alumis Inc.’s price range in the past 12 months?
Alumis Inc. lowest stock price was $2.76 and its highest was $28.29 in the past 12 months.
What is Alumis Inc.’s market cap?
Alumis Inc.’s market cap is $3.27B.
When is Alumis Inc.’s upcoming earnings report date?
Alumis Inc.’s upcoming earnings report date is Mar 25, 2026 which is in 42 days.
How were Alumis Inc.’s earnings last quarter?
Alumis Inc. released its earnings results on Nov 13, 2025. The company reported -$1.06 earnings per share for the quarter, missing the consensus estimate of -$0.932 by -$0.128.
Is Alumis Inc. overvalued?
According to Wall Street analysts Alumis Inc.’s price is currently Undervalued.
Does Alumis Inc. pay dividends?
Alumis Inc. does not currently pay dividends.
What is Alumis Inc.’s EPS estimate?
Alumis Inc.’s EPS estimate is -0.96.
How many shares outstanding does Alumis Inc. have?
Alumis Inc. has 117,506,000 shares outstanding.
What happened to Alumis Inc.’s price movement after its last earnings report?
Alumis Inc. reported an EPS of -$1.06 in its last earnings report, missing expectations of -$0.932. Following the earnings report the stock price went up 4.545%.
Which hedge fund is a major shareholder of Alumis Inc.?
Currently, no hedge funds are holding shares in ALMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alumis Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.57 (43.84% Upside)
$37.57 (43.84% Upside)
Blogger Sentiment
Bearish
ALMS Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $51.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.8%
Last 30 Days ▲ 7.8%
Last 30 Days ▲ 7.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
360.67%
12-Months-Change
Fundamentals
Return on Equity
-66.88%
Trailing 12-Months
Asset Growth
18.29%
Trailing 12-Months
Company Description
Alumis Inc.
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
ALMS Stock 12 Month Forecast
Average Price Target
$37.57
▲(43.84% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---